Stratatech wins $4 million in defense funding for living skin substitute

October 7, 2010 by MassDevice staff

Uncle Sam ponies up $4 million for Stratatech Corp.'s Phase IIb clinical trial of its StrataGraft living human skin substitute.

Stratatech logo

Stratatech Corp. won $3.95 million from the U.S. Dept. of Defense's Armed Forces Institute of Regenerative Medicine.

The Madison, Wis.-based company said the AFIRM cash will fund the Phase IIb clinical trial of its StrataGraft cell-based, tissue-engineered skin substitute.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.


Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp